Solriamfetol

Phase 2

Axsome Therapeutics, Inc. (AXSM)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

AXSMPhase 2$10.3B

Solriamfetol Phase 2 Est. Readout

Solriamfetol• Multiple Sclerosis46

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

3 competitors in Multiple Sclerosis

TEVAocrelizumab

TEVAocrelizumab biosimilar

JAZZSativex

Phase 3

View Full Landscape

Drug Information

Target Indication

Multiple Sclerosis

Clinical Trial

NCT06170970

Last updated: 8/15/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

AXSM

Axsome Therapeutics, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

AXS-12 (reboxetine)Phase 3

Narcolepsy

Solriamfetol 150 mgPhase 3

Excessive Sleepiness

AXS-05 (dextromethorphan and bupropion) oral tabletsPhase 3

Major Depressive Disorder

Solriamfetol 300 mgPhase 3

Binge-Eating Disorder

AXS-05Phase 3

Agitation in Patients With Dementia of the Alzheimer's Type

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts